Table of Contents
1 Industry Outlook 10
1.1 Industry Overview 10
1.2 Industry Trends 11
1.2.1 R&D pipeline in pharmaceutical industry 11
1.2.2 Top pharma drugs by sales in 2017 ($Million) 13
2 Report Outline 16
2.1 Report Scope 16
2.2 Report Summary 16
2.3 Research Methodology 17
2.4 Report Assumptions 17
3 Market Snapshot 19
3.1 Market Definition - Infoholic Research 19
3.2 Biologics patent expiration in US and Europe (2010-2020) 19
3.3 Segmented Addressable Market (SAM) 19
3.4 Trends of the biologics market 20
3.5 Related Markets 21
3.5.1 Over the counter drugs 21
3.5.2 Orphan drugs 22
3.5.3 Human Insulin 23
4 Market Outlook 25
4.1 Market segmentation 25
4.2 PEST Analysis 26
4.3 Porter 5(Five) Forces 27
5 Market Characteristics 28
5.1 DRO - Global Biologics Market Dynamics 28
5.1.1 Drivers 28
5.1.1.1 Growing incidence of disease across the globe 28
5.1.1.2 Increasing number of biologics approvals 29
5.1.2 Opportunities 30
5.1.2.1 Strong portfolio of product pipeline and huge number of ongoing clinical trials 30
5.1.2.2 Increasing opportunities in emerging markets 31
5.1.3 Restraints 32
5.1.3.1 Challenges associated with biologics production 32
5.1.3.2 Increasing number of biologics going off patent and emergence of biosimilars 33
5.2 DRO - Impact Analysis 33
5.3 Key Stakeholders 35
6 Products: Market Size & Analysis 36
6.1 Overview 36
6.2 Monoclonal antibodies 37
6.3 Recombinant proteins/Hormones 39
6.4 Vaccines 40
6.5 Cell and Gene Therapy 42
6.6 Others 43
7 Applications: Market Size & Analysis 45
7.1 Overview 45
7.2 Cancer 46
7.3 Immunological disorders 46
7.4 Infectious disease 47
7.5 Hematologic disorders 47
7.6 Cardiovascular disease 48
7.7 Others 48
8 Regions: Market Size and Analysis 49
8.1 Overview 49
8.2 North America 50
8.2.1 US 50
8.2.2 Canada 51
8.3 Europe 51
8.3.1 UK 52
8.3.2 Germany 53
8.3.3 France 53
8.3.4 Spain 53
8.4 Asia Pacific 54
8.4.1 India 54
8.4.2 China 55
8.4.3 Japan 55
8.5 Rest of the World 55
9 Competitive Landscape 57
9.1 Overview 57
10 Vendor Profiles 60
10.1 F. Hoffmann-La Roche 60
10.1.1 Overview 60
10.1.2 Business Unit 63
10.1.3 Geographic Presence 63
10.1.4 Business Focus 64
10.1.5 SWOT Analysis 64
10.1.6 Business Strategy 65
10.2 Sanofi S.A. 66
10.2.1 Overview 66
10.2.2 Business Units 70
10.2.3 Geographic Presence 71
10.2.4 Business Focus 71
10.2.5 SWOT Analysis 72
10.2.6 Business Strategies 72
10.3 Amgen Inc. 73
10.3.1 Overview 73
10.3.2 Geographic Presence 77
10.3.3 Business Focus 77
10.3.4 SWOT Analysis 79
10.3.5 Business Strategies 80
10.4 Novo Nordisk A/S 81
10.4.1 Overview 81
10.4.2 Business Units 84
10.4.3 Geographic Presence 85
10.4.4 Business Focus 85
10.4.5 SWOT Analysis 86
10.4.6 Business Strategies 86
10.5 AbbVie Inc. 87
10.5.1 Overview 87
10.5.2 Geographic Presence 90
10.5.3 Business Focus 90
10.5.4 SWOT Analysis 91
10.5.5 Business Strategies 91
10.6 Johnson & Johnson 92
10.6.1 Overview 92
10.6.2 Business Units 96
10.6.3 Geographic Revenue 96
10.6.4 Business Focus 97
10.6.5 SWOT Analysis 98
10.6.6 Business Strategies 98
10.7 Novartis AG 99
10.7.1 Overview 99
10.7.2 Business Units 102
10.7.3 Geographic Revenue 103
10.7.4 Business Focus 104
10.7.5 SWOT Analysis 104
10.7.6 Business Strategies 105
11 Companies to Watch for 106
11.1 Bristol-Myers Squibb 106
11.1.1 Overview 106
11.2 GlaxoSmithKline plc 108
11.2.1 Overview 108
11.3 Merck & Co. 110
11.3.1 Overview 110
11.4 Eli Lilly and Company Ltd. 111
11.4.1 Overview 111
11.5 Teva Pharmaceutical Industries Ltd. 113
11.5.1 Overview 113
11.6 AstraZeneca PLC 114
11.6.1 Overview 114
11.7 Takeda pharmaceuticals 117
11.7.1 Overview 117
Annexure 120
? Acronyms 120